Follow the Sagimet Biosciences Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €648.3m. The latest transaction was reported on 17 August 2026 (Levée d'options). Among the most active insiders: Kemble George. The full history is accessible without an account.
48
Insider Decl.
n/a
Thresholds
€66,172
3 ops.
Buy Volume
€5m
19 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Sagimet Biosciences Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$28.60.
55Σ signal
Buys €66,172€5m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
116,000 shares0Series A Common StockSEC:0001104659-25-010587:0
25 of 48 declarations
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc. is a biopharmaceutical company focused on developing innovative treatments for metabolic diseases. The company is listed on NASDAQ under the ticker symbol SAGE.